Skip to main content

Table 1 Patient information

From: FLT PET/CT imaging of metastatic prostate cancer patients treated with pTVG-HP DNA vaccine and pembrolizumab

Patient # Study arm Soft tissue mets. at baseline Bone mets. at baseline IRAE greater than Gr 1a (week of occurrence) Progression-free survival (weeks)
1 1 Yes Yes None 24
2 1 Yes Yes None 48
3 1 No Yes None 24
4 1 Yes No None 48+
5 1 Yes Yes None 16
6 1 No Yes Hyperthyroidism (6); Hypothyroidism (12) 24
7 2 No Yes Hypothyroidism (36) 36+
8 2 Yes Yes Pancreatitis (30) 48
9 2 Yes Yes None 24
10 2 Yes Yes None 24+
11 2 No Yes Hyperthyroidism (18) 48
12 2 No Yes Adrenal Insufficiency (38) 72+
13 3 Yes Yes Elevated TSH (9) 36+
14 3 Yes No None 24
15 3 Yes Yes None 24
16 3 Yes No Hyperthyroidism (3) 12
17 3 No Yes None 12
  1. aImmune-related adverse events that were at least possibly related to pembrolizumab and /or pTVG vaccine are listed